ALBO News and Press, Albireo Pharma Inc. From 03/07/19

- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH - - Management to host conference call and webcast tod...

BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Cowen an...

Albireo Pharma (NASDAQ: ALBO ) initiated with Buy rating and $62 (131% upside) price target at H.C. Wainwright. More news on: Albireo Pharma, Inc., Centene Corporation, WellCare Health Plans, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day, and reaffirmed its commitment to patients and families living with ...

BOSTON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 8:30 a.m. EST on Marc...

Albireo Pharma ( ALBO ) is developing A4250 targeting a rare pediatric liver disease called Progressive familial intrahepatic cholestasis (PFIC), where bile formation is disrupted, leading to subsequent liver failure. To be clear, the authority on Seeking Alpha for liver diseases is First G...